Ascaris and <font color="blue">growth_1</font> <font color="blue">rates_1</font> <font color="blue">:_1</font> a randomized trial of treatment . 
<br>
<br> <font color="blue">Three_5</font> <font color="blue">hundred_5</font> <font color="blue">forty_5</font> <font color="blue">-_5</font> <font color="blue">one_5</font> <font color="blue">Tanzanian_5</font> <font color="blue">preschool_5</font> <font color="blue">children_5</font> were randomly assigned to levamisole or placebo treatment given at three - month intervals . Weights and heights were measured at the tri - monthly treatment visits for a period of one year . Among the <font color="blue">273_3</font> <font color="blue">children_4</font> <font color="blue">who_1</font> <font color="blue">were_1</font> <font color="blue">seen_1</font> <font color="blue">and_1</font> <font color="blue">weighed_1</font> <font color="blue">at_1</font> <font color="blue">the_1</font> <font color="blue">one_1</font> <font color="blue">-_1</font> <font color="blue">year_1</font> <font color="blue">follow_1</font> <font color="blue">-_1</font> <font color="blue">up_1</font> <font color="blue">visit_1</font> <font color="blue">,_1</font> the rate of weight gain was 8 per cent greater for those receiving levamisole than for placebo - treated controls ( p = .06 ) . In <font color="blue">78_2</font> <font color="blue">children_3</font> <font color="blue">known_1</font> <font color="blue">to_1</font> <font color="blue">be_1</font> <font color="blue">infected_1</font> <font color="blue">with_1</font> <font color="blue">Ascaris_1</font> at baseline , the rate of weight gain was 21 per cent greater in <font color="blue">children_1</font> treated with levamisole than in those receiving placebo ( p = .03 ) . The <font color="blue">rate_1</font> <font color="blue">of_1</font> <font color="blue">height_1</font> <font color="blue">gain_1</font> was no different for treatment and <font color="blue">placebo_1</font> <font color="blue">groups_1</font> <font color="blue">._1</font>